Case Type: Mergers & Acquisitions

Southwestern Energy Co. (NYSE: SWN), relating to its proposed sale to Chesapeake Energy Corp. Under the terms of the agreement, SWN shareholders are expected to receive between 0.0867 shares of Chesapeake common stock per share they own.

Electrameccanica Vehicles Corp. (Nasdaq: SOLO), relating to its proposed merger with Xos, Inc. Under the terms of the agreement, SOLO shareholders are expected to own approximately 21% of the combined company.

Theseus Pharmaceuticals, Inc. (Nasdaq: THRX), relating to its proposed sale to Concentra Biosciences, LLC. Under the terms of the agreement, THRX shareholders are expected to receive between $3.90 and $4.05 in cash per share they own

Via Renewables, Inc. (Nasdaq: VIA), relating to its proposed sale to Retailco, LLC. Under the terms of the agreement, VIA shareholders will receive $11.00 in cash per share they own.

Ambrx Biopharma, Inc. (Nasdaq: AMAM), relating to its proposed sale to Johnson & Johnson. Under the terms of the agreement, AMAM shareholders will receive $28.00 in cash per share they own.

Harpoon Therapeutics, Inc. (Nasdaq: HARP), relating to its proposed sale to Merck. Under the terms of the agreement, HARP shareholders will receive $23.00 in cash per share they own.

Axonics, Inc. (Nasdaq: AXNX), relating to its proposed sale to Boston Scientific Corp. Under the terms of the agreement, AXNX shareholders will receive $71.00 in cash per share they own.

Callon Petroleum Company (NYSE: CPE), relating to its proposed sale to APA Corp. Under the terms of the agreement, CPE shareholders will receive 1.0425 shares of APA per share they own.

FG Group Holdings Inc. (NYSE: FGH), relating to its proposed sale to FG Financial Group, Inc. Under the terms of the agreement, FGH shareholders will receive one share of FG Financial common stock per share they own

Rain Oncology Inc. (Nasdaq: RAIN), relating to its proposed sale to Pathos AI Inc. Under the terms of the agreement, RAIN shareholders are expected to receive $1.16 in cash plus one non-tradable CVR worth up to $0.17 per share they own